Fig. 1.
Sera of LGG patients do not contain IDH1R132H-specific IgG antibodies. a ELISA-based detection scheme of IDH1R132H-specific IgG antibodies. b Serum samples from IDH1R132H-positive LGG patients were screened for mutation-specific IgG antibodies. In 24 out of 27 sera, IDH1R132H peptide-coated wells showed (background) signals comparable to those of healthy controls. Dashed line indicates cut-off for positivity for IDH1R132H-specific IgG defined as the mean of healthy control values + 3 × SD. c IDH1R132H peptide and scrambled peptide-coated wells were incubated with sera from patients that showed increased optical densities (patients 6 and 19; only samples were re-tested when sufficient sera were available). Same experimental setup was used as in (a). Mutant peptide wells did not show increased absorbance when compared to scrambled peptide wells. Assay was performed in triplicate for all 27 patient sera. Data are represented as mean ± SEM. αIDH1R132H: primary anti-IDH1R132H antibody, positive control